Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

Tricida raises $55m for kidney disease treatment By PBR Staff Writer
Clinical stage, biopharmaceutical firm Tricida has raised $55m in funding for late-stage trials of its lead candidate, TRC101, in patients with kidney disease.
Drug Research > Drug Discovery & Development > News
Vtesse secures $17m in additional Series A funding Vtesse, a company committed to developing drugs that will benefit patients with extremely rare, life-threatening diseases, has secured $17m in additional Series A funding in support of its global, pivotal clinical trial of VTS-270 for Niemann-Pick Type C1 disease (“NPC”).
Drug Research > Drug Discovery & Development > News InflaRx raises $34m for phase II development of IFX-1 anti-complement C5a antibody By PBR Staff Writer
German Biopharmaceutical firm InflaRx has raised $34m in a Series C financing round to advance clinical phase II development of the lead drug candidate IFX-1.
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Hybrigenics Services - Protein Interactions Expert
Who else knows your protein better than you? Who else knows proteins interactions better than us?
Drug Research > Drug Discovery & Development > Suppliers
InflaRx raises $34m for phase II development of IFX-1 anti-complement C5a antibody
By PBR Staff Writer
German Biopharmaceutical firm InflaRx has raised $34m in a Series C financing round to advance clinical phase II development of the lead drug candidate IFX-1.
Drug Research > Drug Discovery & Development > News
Synthorx raises $10m to develop and scale novel protein therapeutics
Synthorx has completed a $10m Series B financing, led by RA Capital Management and joined by Series A investors Avalon Ventures and Correlation Ventures.
Drug Research > Drug Discovery & Development > News
VBI Vaccines applies eVLP Platform to develop novel vaccine candidate to prevent Zika virus
VBI Vaccines has applied its clinical-stage eVLP Platform to the development of a novel vaccine candidate to prevent Zika virus infection.
Drug Research > Drug Discovery & Development > News
Vernalis achieves milestone in oncology drug discovery collaboration with Servier
Vernalis and Servier announced the achievement of a new milestone in their first oncology drug discovery collaboration, triggering a payment of €500K to Vernalis.
Drug Research > Drug Discovery & Development > News
Poxel closes €26.5m capital increase
POXEL, a biopharmaceutical company focused on the development of innovative treatments for type 2 diabetes, announced the closing of a capital increase of 3,400,000 new ordinary shares without preferential subscription rights reserved for a category of investors for a total amount of €26.5m.
Drug Research > Drug Discovery & Development > News
Ardelyx agrees to raise $110m in private placement
By PBR Staff Writer
Clinical-stage biopharmaceutical firm Ardelyx has agreed to raise $110m in a private placement.
Drug Research > Drug Discovery & Development > News
Panther Biotechnology starts formal development of Transferrin Doxorubicin conjugate
Panther Biotechnology has initiated the formal drug development process for its lead compound, Transferrin Doxorubicin (TRF-DOX).
Drug Research > Drug Discovery & Development > News
ProMIS starts new program to find novel Alzheimer’s disease targets on toxic strains of protein tau
ProMIS Neurosciences has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein tau, which, like neurotoxic strains of Amyloid beta (Aβ), are implicated in the development of Alzheimer’s disease (AD).
Drug Research > Drug Discovery & Development > News
Avacta, Glythera collaborate to develop alternatives to antibody drug conjugates
By PBR Staff Writer
Avacta Group and Glythera have partnered to develop a new, highly targeted bio-therapeutics as an alternative to established antibody drug conjugates.
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests